BioNTech SE
NASDAQ:BNTX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
78.36
124.71
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
BioNTech SE
Wall Street
Price Targets
BNTX Price Targets Summary
BioNTech SE
According to Wall Street analysts, the average 1-year price target for
BNTX
is 139.4 USD
with a low forecast of 100.23 USD and a high forecast of 180.02 USD.
BNTX Last Price Targets
BioNTech SE
The latest public price target was made on Nov 13, 2024 by
Daina Graybosch
from
Leerink Partners
,
who expects
BNTX
stock to
rise by 7%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Daina Graybosch
Leerink Partners
|
121
USD
Upside 7% |
1 month ago
Nov 13, 2024
|
BioNTech (BNTX) PT Raised to $121 at Leerink Partners
StreetInsider
|
Chris Shibutani
Goldman Sachs
|
137
USD
Upside 21% |
1 month ago
Nov 8, 2024
|
Goldman Sachs Upgrades BioNTech (BNTX) to Buy
StreetInsider
|
Etzer Darout
BMO Capital
|
126
USD
Upside 11% |
1 month ago
Nov 4, 2024
|
BioNTech (BNTX) PT Raised to $126 at BMO Capital
StreetInsider
|
Terence Flynn
Morgan Stanley
|
145
USD
Upside 28% |
3 months ago
Sep 23, 2024
|
Morgan Stanley upgrades BioNTech on cancer potential of BNT327
TheFly
|
Akash Tewari
Jefferies
|
150
USD
Upside 32% |
3 months ago
Sep 17, 2024
|
Jefferies Upgrades BioNTech (BNTX) to Buy
StreetInsider
|
Tazeen Ahmad
Bank of America Securities
|
150
USD
Upside 32% |
3 months ago
Sep 16, 2024
|
BioNTech (BNTX) PT Raised to $150 at BofA Securities
StreetInsider
|
|
Akash Tewari
Jefferies
|
96
USD
Downside 15% |
3 months ago
Sep 13, 2024
|
BioNTech (BNTX) PT Raised to $96 at Jefferies
StreetInsider
|
Emmanuel Papadakis
Deutsche Bank
|
95
USD
Downside 16% |
4 months ago
Aug 6, 2024
|
BioNTech upgraded to Buy from Hold at Deutsche Bank
TheFly
|
|
Terence Flynn
Morgan Stanley
|
93
USD
Downside 18% |
4 months ago
Aug 5, 2024
|
BioNTech (BNTX) PT Lowered to $93 at Morgan Stanley
StreetInsider
|
Yifeng Liu
HSBC
|
101
USD
Downside 11% |
4 months ago
Aug 2, 2024
|
HSBC Upgrades BioNTech (BNTX) to Buy
StreetInsider
|
|
Raghuram Selvaraju
H.C. Wainwright
|
113
USD
Downside 0% |
5 months ago
Jun 26, 2024
|
H.C. Wainwright Reiterates Buy Rating on BioNTech (BNTX)
StreetInsider
|
Cory Kasimov
Evercore ISI
|
100
USD
Downside 12% |
7 months ago
May 13, 2024
|
Evercore ISI Starts BioNTech (BNTX) at In Line
StreetInsider
|
|
Etzer Darout
BMO Capital
|
122
USD
Upside 7% |
7 months ago
May 7, 2024
|
BioNTech (BNTX) PT Lowered to $122 at BMO Capital
StreetInsider
|
|
Yifeng Liu
HSBC
|
90
USD
Downside 21% |
9 months ago
Mar 22, 2024
|
BioNTech (BNTX) PT Lowered to $90 at HSBC, 'near-term COVID-19 revenue still remains a risk overhang'
StreetInsider
|
|
Chris Shibutani
Goldman Sachs
|
91
USD
Downside 20% |
9 months ago
Mar 21, 2024
|
BioNTech (BNTX) PT Lowered to $91 at Goldman Sachs
StreetInsider
|
William Maughan
Canaccord Genuity
|
171
USD
Upside 51% |
9 months ago
Mar 21, 2024
|
Canaccord Genuity Reviews BioNTech (BNTX) Post Earnings
StreetInsider
|
|
Etzer Darout
BMO Capital
|
123
USD
Upside 8% |
9 months ago
Mar 21, 2024
|
BioNTech (BNTX) PT Lowered to $123 at BMO Capital
StreetInsider
|
|
Unknown Analyst
Goldman Sachs
|
156
USD
Upside 37% |
1 year ago
Jan 31, 2023
|
Goldman Sachs Maintains Neutral on BioNTech, Lowers Price Target to $156
Benzinga
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is BNTX's stock price target?
Price Target
139.4
USD
According to Wall Street analysts, the average 1-year price target for
BNTX
is 139.4 USD
with a low forecast of 100.23 USD and a high forecast of 180.02 USD.
What is BioNTech SE's Revenue forecast?
Projected CAGR
-5%
For the last 5 years the
compound annual growth rate for
BioNTech SE's revenue is
97%.
The projected
CAGR
for the next 4 years is
-5%.
You don't have any saved screeners yet
